Navigation Links
Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine
Date:2/3/2009

in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries such as adverse neurological outcomes. For more information about Cardium's InnerCool subsidiary and patient temperature modulation, including InnerCool's new RapidBlue(TM) System, which just received FDA clearance, and its CoolBlue(TM) System, please visit http://www.innercool.com.

Cardium also has two biologic candidates in clinical development. Cardium's Tissue Repair Company subsidiary (TRC) is focused on the development of growth factor therapeutics for the treatment of severe chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or twice for the potential treatment of non-healing diabetic foot ulcers. Other potential applications for TRC's Gene Activated Matrix(TM) (GAM) technology include therapeutic angiogenesis (cardiovascular ischemia, peripheral arterial disease) and orthopedic products, including hard tissue (bone) and soft tissue (ligament, tendon, cartilage) repair. For more information about Cardium's Tissue Repair Company subsidiary, please visit http://www.t-r-co.com.

Cardium's Generx product candidate (alferminogene tadenovec, Ad5FGF-4) is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. For more information about Cardium Therapeutics and its businesses, products and thera
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
3. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
4. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
5. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
6. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
7. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
8. Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO
9. Stem Cell Therapy to Skyrocket by 2017
10. Team demos safety of RNA therapy
11. First European IGRT School Takes Place for Radiotherapy Practitioners in UK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Technology Applications International ... that its wholly-owned subsidiary Renuell Int,l, Inc. has signed ... and Space Administration ("NASA") at the Johnson Space Center ... See photos: tapplic.com/houstonphotos/ ... are very pleased to announce our latest, exclusive agreement ...
(Date:9/2/2014)... September 02, 2014 Opertech Bio, ... highly efficient, cost effective approach to sensory evaluation, ... 8,820,265 by the U.S. Patent and Trademark Office, ... , “Opertech’s taste evaluation technology called ... automated high throughput system for rapid characterization of ...
(Date:9/2/2014)... 2, 2014  Xencor, Inc. (NASDAQ: ... monoclonal antibodies for the treatment of autoimmune diseases, ... the appointment of Debra Zack , M.D., ... of Lloyd Rowland , senior vice president, ... "Debra,s expertise in biologics clinical development and ...
(Date:9/2/2014)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... targeting specific pathogens that cause serious infections and ... preclinical toxicology study of SYN-004. Per U.S. Food ... was required to move the Company,s lead anti-infective, ... effects of Clostridium difficile (C. difficile), ...
Breaking Biology Technology:Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5
... Micromet, Inc. (Nasdaq: ... for the treatment of cancer, inflammation and autoimmune diseases, ... Itin, will present at the Cowen Health Care Conference ... on Tuesday, March 17, 2009. A simultaneous webcast ...
... Company Receives Allowance of Patent Claims in the ... Highlighted in Nature Biotechnology -BRITISH COLUMBIA, Canada, March ... IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com ), a ... monoclonal antibodies based on its Dynamic Cross Linking ...
... Wis., March 6 Mach One Corporation (Pink ... subsidiary, Modular Process Constructors LLC, is changing its ... vision, and announces that it received a contract ... consumer health company. The contract is for a ...
Cached Biology Technology:Micromet to Present at the Cowen Health Care Conference on March 17, 2009 2Micromet to Present at the Cowen Health Care Conference on March 17, 2009 3Micromet to Present at the Cowen Health Care Conference on March 17, 2009 4InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies 2InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies 3Mach One Subsidiary Modular Process Constructors LLC Changes Name to MPS BioPharm to Better Reflect its Vision 2
(Date:9/2/2014)... with the participation of the University of Granada has ... place in the Iberian Peninsula around the mid Holocene ... dust coming from the Sahara increased. The data came ... Alpine lake in Sierra Nevada (Granada) , This study, ... based on the sedimentation of atmospheric dust from the ...
(Date:9/2/2014)... ideal source of nutrition for infants and it ... evolution and civilizations of human beings. Unlike our ... of bacterial species, including some opportunistic pathogens of ... scientists and physicians. , Indeed, the existence of ... of co-evolutionary and co-adaptive interactions between the microbiome ...
(Date:9/2/2014)... 2014 A study published in the September ... American Academy of Child and Adolescent Psychiatry ... psychiatric diagnosis had an increased risk of developing ... Using data from the nationwide Danish registers, a ... Nielsen, Psychiatry, Aalborg University Hospital, Denmark, studied 48,299children ...
Breaking Biology News(10 mins):Scientists obtain new data on the weather 10,000 years ago from sediments of a lake in Sierra Nevada 2Are human breast milk microbiome 'neutral'? 2Are human breast milk microbiome 'neutral'? 3Risk of diabetes in children and adolescents exposed to antipsychotics 2
... for many people with depression and anxiety disorders, and ... care providers, according to researchers who analyzed the results ... shown to have tremendous benefits for mental health," says ... Program at Southern Methodist University in Dallas. "The more ...
... at Ume University and the Sahlgrenska Academy at the University ... can be found in fish that have been swimming in ... found in higher concentrations in the blood of fish than ... this hormone can lead to infertility in fish. The ...
... neurodegenerative disease spinocerebellar ataxia type 5 (SCA5) damages nerve ... report that the defective protein responsible for the disease ... inside neurons. The study appears in the April 5 ... ( www.jcb.org ). SCA5 results from a faulty ...
Cached Biology News:Mental health providers should prescribe exercise more often for depression, anxiety 2Medicine residues may threaten fish reproduction 2Defective protein is a double hit for ataxia 2
... QRT-PCR Mixes are formulated for use in ... SYBR Green. One-step QRT-PCR mixes offer a ... The pipetting steps are minimised, making the ... ,The 2x ABsolute QRT-PCR Mix is supplied ...
... of environmental and pathophysiological stressful conditions trigger ... known as heat shock proteins (HSPs), more ... The Hsp90 family of proteins in ... beta, Grp94, and Trap-1 (Hsp75). It was ...
... bespoke, cost-effective solutions for complex protein processing and production ... experience to help you develop a solution to your ... , do ... transfer all methodology to your own ...
... The Schleicher & Schuell BioScience Arraying ... dedicated to custom protein and nucleic ... project teams, comprised of R&D, Engineering, ... closely with collaborators every step of ...
Biology Products: